Thompson Siegel & Walmsley LLC Zynerba Pharmaceuticals, Inc. Transaction History

Thompson Siegel & Walmsley LLC

  • $6.71 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 11, 2019
SELL
$2.89 - $7.91 $55,777 - $152,663
-19,300 Closed
0 $0
Q3 2018

Nov 08, 2018
BUY
$5.59 - $10.45 $107,887 - $201,685
19,300 New
19,300 $157,000

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Thompson Siegel & Walmsley LLC Portfolio

Follow Thompson Siegel & Walmsley LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thompson Siegel & Walmsley LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thompson Siegel & Walmsley LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email